Inhibiting tumor-cell growth by novel truncated staphylococcal enterotoxin C2 mutant.
Clinical application of staphylococcal enterotoxin C2 (SEC2) was restricted during the cure of malignant tumor due to its side-effects. The aim of this study was to obtain SEC2 mutant, preserving the important functional sites responsible for the T-cell stimulatory activities but removing the sites responsible for emetic activity, through truncation of SEC2. It would efficiently solve the question of SEC2 side-effect. According to the results of methyl thiazol tetrazolium (MTT) assay in vitro, novel truncated SEC2 mutant (NSM) efficiently stimulated T-cell proliferation and inhibited the growth of such tumor cells as human colorectal cancer cells (Cx-1) and human breast cancer cells (MCF-7) in vitro. Activities of T cell stimulating and anti-tumor of NSM were similar to those of SEC2. According to results of animal experiments, the mutant no longer induced emetic response even if the dose was a 10-fold excess of the amount of SEC2 required. And also, NSM obviously inhibited the tumor growth in tumor-bearing mice. Therefore, we obtained novel truncated staphylococcal enterotoxin C2 mutant, which could efficiently inhibit the growth of tumor cells. It will become novel anti-tumor agents with the lowest side-effects and best treatment effects in clinic.
Laboratory of Biomaterials and Biopharmaceuticals, School of Life Sciences, Liaoning University, Shenyang 110036, China.
Jing
J
Hui
Fang
F
Xiao
Hui
H
Li
Xiaojin
X
Cui
Hongsheng
H
Liu
Fengqing
F
Hu
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000276:immunology / Q000473:pathology; D004768:Enterotoxins / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D051379:Mice; D050505:Mutant Proteins / Q000276:immunology*; D013211:Staphylococcus aureus / Q000276:immunology; D018089:Superantigens / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014839:Vomiting / Q000517:prevention & control
D000970:Antineoplastic Agents; D004768:Enterotoxins; D050505:Mutant Proteins; D018089:Superantigens; C034959:enterotoxin C, staphylococcal